Japanska läkemedelsmyndigheten (PMDA) ger sitt stöd för en expansion av PledOx® fas III-program till att inkludera japanska patienter
13 juin 2018 02h30 HE
|
PledPharma AB
Stockholm, 13 juni 2018. PledPharma AB (publ) och deras partner Solasia Pharma K.K. (Solasia) meddelar idag att den japanska läkemedelsmyndigheten (PMDA) som följd av mötet med PledPharma och Solasia,...
Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives
14 janv. 2018 21h12 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO Japan, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the...
Full Product Approval In Japan Received By Mesoblast Licensee
18 sept. 2015 01h23 HE
|
Mesoblast
NEW YORK CITY and MELBOURNE, Australia, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full...